LAB Valuation

Standard BioTools Inc

Add to Watchlist

Advanced Chart

1.230

+0.01(0.820%)1D

Overview
Forecast
Valuation
Earnings

LAB Relative Valuation

LAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LAB is overvalued; if below, it's undervalued.

Historical Valuation

Standard BioTools Inc (LAB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.66 is considered Overvalued compared with the five-year average of -12.46. The fair price of Standard BioTools Inc (LAB) is between 0.54 to 1.16 according to relative valuation methord. Compared to the current price of 1.23 USD , Standard BioTools Inc is Overvalued By 6.32%.

Relative Value

Fair Zone

0.54-1.16

Current Price：1.23

6.32%

Overvalued

-9.46

Trailing

Forward

-6.16

EV/EBITDA

Standard BioTools Inc. (LAB) has a current EV/EBITDA of -6.16. The 5-year average EV/EBITDA is -7.92. The thresholds are as follows: Strongly Undervalued below -16.59, Undervalued between -16.59 and -12.26, Fairly Valued between -3.59 and -12.26, Overvalued between -3.59 and 0.74, and Strongly Overvalued above 0.74. The current Forward EV/EBITDA of -6.16 falls within the Historic Trend Line -Fairly Valued range.

-3.07

EV/EBIT

Standard BioTools Inc. (LAB) has a current EV/EBIT of -3.07. The 5-year average EV/EBIT is -6.16. The thresholds are as follows: Strongly Undervalued below -13.14, Undervalued between -13.14 and -9.65, Fairly Valued between -2.67 and -9.65, Overvalued between -2.67 and 0.82, and Strongly Overvalued above 0.82. The current Forward EV/EBIT of -3.07 falls within the Historic Trend Line -Fairly Valued range.

3.66

Standard BioTools Inc. (LAB) has a current PS of 3.66. The 5-year average PS is 2.56. The thresholds are as follows: Strongly Undervalued below 0.26, Undervalued between 0.26 and 1.41, Fairly Valued between 3.71 and 1.41, Overvalued between 3.71 and 4.86, and Strongly Overvalued above 4.86. The current Forward PS of 3.66 falls within the Historic Trend Line -Fairly Valued range.

-8.44

P/OCF

Standard BioTools Inc. (LAB) has a current P/OCF of -8.44. The 5-year average P/OCF is -4.36. The thresholds are as follows: Strongly Undervalued below -13.04, Undervalued between -13.04 and -8.70, Fairly Valued between -0.02 and -8.70, Overvalued between -0.02 and 4.32, and Strongly Overvalued above 4.32. The current Forward P/OCF of -8.44 falls within the Historic Trend Line -Fairly Valued range.

-8.13

P/FCF

Standard BioTools Inc. (LAB) has a current P/FCF of -8.13. The 5-year average P/FCF is -3.98. The thresholds are as follows: Strongly Undervalued below -11.56, Undervalued between -11.56 and -7.77, Fairly Valued between -0.19 and -7.77, Overvalued between -0.19 and 3.60, and Strongly Overvalued above 3.60. The current Forward P/FCF of -8.13 falls within the Undervalued range.

Standard BioTools Inc (LAB) has a current Price-to-Book (P/B) ratio of 1.10. Compared to its 3-year average P/B ratio of -0.33 , the current P/B ratio is approximately -433.48% higher. Relative to its 5-year average P/B ratio of 1.27, the current P/B ratio is about -13.49% higher. Standard BioTools Inc (LAB) has a Forward Free Cash Flow (FCF) yield of approximately -22.57%. Compared to its 3-year average FCF yield of -35.82%, the current FCF yield is approximately -36.99% lower. Relative to its 5-year average FCF yield of -28.10% , the current FCF yield is about -19.66% lower.

1.10

P/B

Median3y

-0.33

Median5y

1.27

-22.57

FCF Yield

Median3y

-35.82

Median5y

-28.10

Competitors Valuation Multiple

The average P/S ratio for LAB's competitors is 2.07, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB) exhibits a P/S ratio of 3.66, which is 76.45% above the industry average. Given its robust revenue growth of -57.87%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LAB.O

Standard BioTools Inc

Treace Medical Concepts Inc

1.87

6.60%

435.26M

Performance Decomposition

Market capitalization of LAB decreased by 42.25% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.71 to -3.35.

The secondary factor is the Margin Expansion, contributed -8.24%to the performance.

Overall, the performance of LAB in the past 1 year is driven by P/E Change. Which is more unsustainable.

-57.87%

37.21M → 15.67M

Revenue Growth

-8.24%

-122.88 → -112.76

Margin Expansion

23.86%

-2.71 → -3.35

P/E Change

-42.25%